Systemic Lupus Erythematosus Clinical Trials in Miami, Florida

6 studies are recruiting for systemic lupus erythematosus in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

   The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

   Stage

   Phase 3

   Ages

   16 and older

   Site

   Sl0044 50747, Miami, Florida

   Locations

   245 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT06617325 on ClinicalTrials.gov

2. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

   Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, …

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Allied Biomedical Research Institute /ID# 284408, Miami, Florida

   Locations

   15 in total

   Run by

   AbbVie

   See if you can join NCT07607964 on ClinicalTrials.gov

3. A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

   The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with activ…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Vitaly Clinical Research, Miami, Florida

   Locations

   58 in total

   Run by

   Amgen

   See if you can join NCT06570798 on ClinicalTrials.gov

4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

   The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Investigative Site, Miami, Florida

   Locations

   34 in total

   Run by

   Ventus Therapeutics U.S., Inc.

   See if you can join NCT07260877 on ClinicalTrials.gov

5. A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

   The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Research Site, Miami, Florida

   Locations

   107 in total

   Run by

   AstraZeneca

   See if you can join NCT07430306 on ClinicalTrials.gov

6. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

   The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participa…

   Stage

   Phase 2

   Ages

   12 to 70

   Site

   Miami Dermatology and Laser Research, Miami, Florida

   Locations

   12 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07570862 on ClinicalTrials.gov